ifosfamide / Generic mfg.  >>  Phase 2
Welcome,         Profile    Billing    Logout  

89 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
ifosfamide / Generic mfg.
ACTRN12606000350527: Outpatient-based fractionated Ifosfamide, Carboplatin, Etoposide (ICE) chemotherapy supported with pegfilgrastim for salvage and stem cell mobilisation in transplant eligible patients with relapsed or refractory diffuse large B-cell lymphoma and Hodgkin lymphoma

Recruiting
2
40
 
Amgen, Amgen
Relapsed or refractory diffuse large B-cell lymphoma and Hodgkin lymphoma
 
 
SSGXX, NCT00790244 / 2007-001152-39: A Scandinavian Sarcoma Group Protocol for Patients With High-risk Soft Tissue Sarcoma of the Extremities and Trunk Wall

Recruiting
2
188
Europe
doxorubicin , ifosfamide, Doxorubicin, Holoxan, doxorubicin, ifosfamide
Oslo University Hospital, Scandinavian Sarcoma Group
Soft Tissue Sarcoma, Non Metastatic Disease
10/12
10/22
2013-000762-11: A randomized double-blind phase II study evaluating the role of maintenance therapy with cabozantinib in High Grade Uterine Sarcoma (HGUtS) after stabilization or response to doxorubicin +/- ifosfamide following surgery or in metastatic first line treatment

Ongoing
2
90
Europe, RoW
Cabozantinib, XL184, Film-coated tablet
European Organisation for Research and Treatment of Cancer (EORTC), Exelixis, European Organisation for Research and Treatment of Cancer (EORTC)
High Grade Undifferentiated Uterine Sarcoma (HGUS), Uterine Sarcoma, Diseases [C] - Cancer [C04]
 
 
2014-003031-19: This is a study to valuate the activity and feasibility of a new sequential chemoimmunotherapy program in patients with Diffuse Large B Cell Lymphoma and central nervous system involvement at diagnosis or relapse.

Ongoing
2
76
Europe
METROTREXATO, RITUXIMAB, CITARABINA, IFOSFAMIDE, CARBOPLATINO, ETOPOSIDE, TIOTEPA, BCNU, cytarabine liposome intrathecal, Solution for injection, Concentrate for solution for infusion, Injection, Solution for infusion, Powder for solution for injection, Powder for concentrate for solution for infusion, Powder for solution for infusion, Suspension for injection, methotrexate, Cytarabine, rituximab, Etoposide, carboplastin, hydrocortisone
IELSG (INTERNATIONAL EXTRANODAL LYMPHOMA STUDY GROUP), International Extranodal Lymphoma Study Group, IELSG, Erasmus MC, NKI-AVL, LUMC
systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, systemic diffuse large B-cell lymphoma with central nervous system involvement at diagnosis or relapse, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT01946529: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Active, not recruiting
2
24
US
vincristine, Oncovin(R), doxorubicin, Adriamycin(R), cyclophosphamide, Cytoxan(R), ifosfamide, Ifex(R), etoposide, VP-16, Vepesid(R), temozolomide, Temodar(R), temsirolimus, CCI-779, Torisel^TM, bevacizumab, rhumab VEGF, Avastin(R), sorafenib, BAY-43-9006, Nexavar(R), surgery, therapeutic conventional surgery, radiation, proton beam radiation therapy, external beam radiation therapy, brachytherapy
St. Jude Children's Research Hospital, University of Tennessee, University of Florida, Nemours Children's Clinic
Desmoplastic Small Round Cell Tumor, Ewing Sarcoma of Bone or Soft Tissue, Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
08/15
07/26
2006-003243-23: A Phase II Study of OXALIPLATIN and GEMCITABINE in Combination with IFOSFAMIDE plus RITUXIMAB (R-GIFOX) as 2nd-line Chemotherapy in Relapsed and Primary Refractory Lymphoma

Ongoing
2
45
Europe
GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG, GEMZAR*INFUS 1FL 1G POLV, GEMZAR*1FL 200MG POLV, ELOXATIN*IV 1FL POLV 50MG, MABTHERA*EV 1FL 50ML 500MG, HOLOXAN*IV 1FL 1G+FL 50ML SOLV, MABTHERA*EV 2F 10ML 100MG, ELOXATIN*IV 1FL POLV 100MG
ISTITUTO NAZIONALE PER LO STUDIO E LA CURA DEI TUMORI - FONDAZIONE \"G. PASCALE\"
Patients with Relapsed and Primary Refractory Lymphoma
 
 
2007-000699-18: Randomized phase II study of two associations of rituximab and chemotherapy, with a pet-driven strategy, in patients from 18 to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted IPI

Ongoing
2
222
Europe
PREDNISONE, RITUXIMAB, DOXORUBICINE, CYCLOPHOSPHAMIDE, VINDESINE, BLEOMYCIN, METHOTREXATE, G-CSF, VINCRISTINE, IFOSFAMIDE, ETOPOSIDE, CYTARABINE, CARMUSTINE, MELPHALAN, autologous stem cells, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN, Solu-Medrol®, Medrol®, Mabthera 100mg, Mabthera 500mg, ADRIBLASTINA®, ENDOXAN®, BLEOMYCINE®, LEDERTREXATE®, Neupogen®, VINCRISIN®, VEPESID®, HOLOXAN®, Cytosar®, Alkeran®, VORINA®, NITRUMON®, ZEVALIN
Hospices Civils de Lyon, Groupe d\'Etude des Lymphomes de l\'Adulte(GELA)
CD20+ diffuse large B-cell lymphoma
 
 
2008-003316-36: NON PEGILATED LIPOSOMIAL DOXORUBICIN (TLC D-99) IN ASSOCIATION WITH IFOSFAMIDE IN PATIENTS WITH METASTATIC SOFT TISSUE SARCOMA

Ongoing
2
32
Europe
MYOCET, HOLOXAN*EV 1FL 1G, MYOCET, HOLOXAN*EV 1FL 1G
CENTRO DI RIFERIMENTO ONCOLOGICO DI AVIANO
METASTATIC SOFT TISSUE SARCOMAS
 
 
2014-004678-41: Etude prospective de phase II d’évaluation d’une prise en charge multimodale des métastases ganglionnaires inguinales des carcinomes épidermoïdes du pénis par lymphadénectomie bilatérale et chimiothérapie TIP (paclitaxel, ifosfamide et cisplatine).

Not yet recruiting
2
37
Europe
Concentrate for solution for infusion, Solution for infusion, PACLITAXEL, IFOSFAMIDE, CISPLATINE
UNICANCER, Institutionels
Tumeur du pénis, Tumeur du pénis, Diseases [C] - Cancer [C04]
 
 
PIVeR, NCT03458260 / 2017-000719-17: Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma

Active, not recruiting
2
74
Europe
Pixantrone, Pixuvri, Ifosfamide, Holoxan, Etoposide, Vepeside, Rituximab, Mabthera, Transplant
The Lymphoma Academic Research Organisation
Aggressive Non-Hodgkin Lymphoma
06/19
03/25
NCT02329080: New Combination of Chemoimmunotherapy for Systemic B-cell Lymphoma With Central Nervous System Involvement

Active, not recruiting
2
76
Europe, RoW
Methotrexate, Rituximab, Cytarabine, Thiotepa, liposomial cytarabine, Etoposide, Ifosfamide, Carmustine, whole brain radiotherapy
International Extranodal Lymphoma Study Group (IELSG)
Diffuse Large B-cell Lymphoma
08/19
12/23
NCT01602666: Chemotherapy Followed by Radiation Therapy in Treating Younger Patients With Newly Diagnosed Localized Central Nervous System Germ Cell Tumors

Active, not recruiting
2
262
Canada, US, RoW
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy
Children's Oncology Group, National Cancer Institute (NCI)
Central Nervous System Nongerminomatous Germ Cell Tumor, Childhood Central Nervous System Germinoma
06/24
06/24
UN-RESARC, NCT03651375: Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall

Active, not recruiting
2
46
Europe
Sequential chemotherapy - 3 courses of AI, Hypofractionated radiotherapy
Maria Sklodowska-Curie National Research Institute of Oncology
Sarcoma, Fibrosarcoma, Leiomyosarcoma, Liposarcoma, Myosarcoma, Histiocytic Sarcoma, Synovial Sarcoma, Lymphangiosarcoma, Malignant Peripheral Nerve Sheath Tumors, Myxofibrosarcoma, Myxoid Liposarcoma, Undifferentiated Sarcoma, Pleomorphic Liposarcoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, Pleomorphic Rhabdomyosarcoma, Malignant Triton Tumor
12/19
03/22
SINTART 1, NCT02099175 / 2013-000075-33: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients

Active, not recruiting
2
41
Europe
Cisplatin, CDDP, Docetaxel, Taxotere, 5-fluorouracil, Adrucil, Etoposide, Vepesid, Adriamycin, Doxorubicin, Ifosfamide, Ifex, Leucovorin, Folinic acid, Radiotherapy - Patients needing Elective Nodal Volume (ENI), Radiotherapy - Patients not needing ENI, Radiotherapy - Patients needing curative neck irradiation
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Regione Lombardia
Sinonasal Tumors
01/20
01/24
NCT02771743: Response-based Treatment of High-risk Neuroblastoma

Recruiting
2
54
RoW
Cisplatin, Doxorubicin, Etoposide, Cyclophosphamide, Ifosfamide, Carboplatin, Tandem HDCT/auto-SCT, Radiotherapy, Interleukin-2, Isotretinoin, MIBG
Samsung Medical Center
Newly Diagnosed High Risk Neuroblastoma
03/20
03/23
NCT02784015: Response Based Treatment for Children With Unresectable Localized Soft Tissue Sarcoma

Recruiting
2
41
RoW
Cisplatin, Etoposide, Doxorubicin, Cyclophosphamide, Ifosfamide, Carboplatin, Radiotherapy, Thiotepa, Melphalan
Samsung Medical Center
Unresectable Localized Soft Tissue Sarcoma
05/20
05/23
SINTART2, NCT02099188 / 2013-000580-93: Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients

Active, not recruiting
2
27
Europe
Cisplatin, CDDP, Docetaxel, Taxotere, 5-fluorouracil, Adrucil, Etoposide, Vepesid, Adriamycin, Doxorubicin, Ifosfamide, Ifex, Leucovorin, Folinic acid, Radiotherapy - Patients needing Elective Nodal Volume (ENI), Radiotherapy - Patients not needing ENI, Radiotherapy - Patients needing curative neck irradiation
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Regione Lombardia
Unresectable Sinonasal Tumors
06/20
01/24
NICE, NCT06438614: A Study Of Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

Completed
2
47
Europe
HITS, Naxitamab + GM-CSF cycles, NICE
Fundació Sant Joan de Déu
Refractory Neuroblastoma, Soft Tissue Cancer
07/23
10/23
2020-002777-95: Sequential neoadjuvant ifosfamide and doxorubicin in localized high-grade soft tissue sarcoma of extremities and trunk wall

Not yet recruiting
2
50
Europe
Ifosfamide, Doxorubicin, Powder for concentrate for solution for injection/infusion, Injection, Holoxan, Adriamycin
Oslo University Hospital, Tildelte forskningsmidler
Soft Tissue Sarcoma, Cancer, Diseases [C] - Cancer [C04]
 
 
2014-000043-32`ACTRN12620000854932: A Phase 2 study of Paclitaxel and Ifosfamide plus either Cisplatin or Carboplatin for patients with metastatic non-transitional cell carcinoma of the bladder and the urinary tract

Ongoing
2
66
Europe
Paclitaxel, Ifosfamide, Cisplatin, Paclitaxel, Ifosfamide, Cisplatin, Powder for infusion, Solution for infusion, Paclitaxel, IFOSFAMIDE, Cisplatin
Fondazione IRCCS Istituto Nazionale dei Tumori, Fondazione IRCCS Istituto Nazionale dei Tumori
COVID 19
 
 
NU 16H07, NCT03077828: Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
2
43
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplat, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475
Northwestern University, Merck Sharp & Dohme LLC, National Cancer Institute (NCI)
Lymphocyte-Rich Classical Hodgkin Lymphoma, Recurrent Lymphocyte-Depleted Classical Hodgkin Lymphoma, Recurrent Mixed Cellularity Classical Hodgkin Lymphoma, Recurrent Nodular Sclerosis Classical Hodgkin Lymphoma, Refractory Lymphocyte-Depleted Classical Hodgkin Lymphoma, Refractory Mixed Cellularity Classical Hodgkin Lymphoma, Refractory Nodular Sclerosis Classical Hodgkin Lymphoma
12/20
12/24
ChiCTR-OIC-17013701: Phase II study of concurrent Chemoradiotherapy followed by Peg-Asp-IDE(PIDE) for localized Nasal Natural Killer/T-Cell Lymphoma: a prospective single-center clinical trial

Recruiting
2
30
 
concurrent chemoradiotherapy followed by long-acting aspargase (pegylated aspargase, PEG-ASP) combined with Ifosfamide,dexamethasone and Etoposide (PIDE) treatment
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, self-financing
Natural Killer/T-Cell Lymphoma
 
 
NCT01979536: Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Completed
2
137
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Crizotinib, MET Tyrosine Kinase Inhibitor PF-02341066, PF-02341066, PF-2341066, PF02341066, Xalkori, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039
National Cancer Institute (NCI)
Anaplastic Large Cell Lymphoma, ALK-Positive, Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma, Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma
03/21
03/24
ChiCTR1800016587: Comparison of efficacy between GD and IE as second-line chemotherapy regimens in advanced soft tissue sarcoma: a phase II randomized controlled trial

Not yet recruiting
2
266
 
Gemcitabine with Docetaxel ;Ifosfamide with Etoposide
West China Hospital, Sichuan University; West China Hospital, Sichuan University, Self financing
soft tissue sarcoma
 
 
VIDL+ASCT, NCT02544425: VP-16, Ifosfamide, Dexamethasone, L-asparaginase Chemotherapy in Patients With Extranodal Natural Killer T Cell Lymphoma

Recruiting
2
27
RoW
Etoposide, VP-16, Ifosfamide, Dexamethasone, L-asparaginase, Busulfan, Melphalan
Samsung Medical Center
Extranodal NK-T-Cell Lymphoma
08/21
11/21
2021-001085-37: Bintrafusp alfa and Doxorubicin Hydrochloride in Treating Patients With Advanced Sarcoma. Chimiothérapie néo-adjuvante plus retifanlimab (INCMGA00012)chez les patients porteurs de sarcomes rétropéritoneaux sélectionnés : une étude randomisée de phase II.

Not yet recruiting
2
66
Europe
Retifanlimab, DOXORUBICIN, HOLOXAN, INCMGA00012, Solution for infusion, Powder for infusion, DOXORUBICIN, HOLOXAN (Ifosfamide)
Institut Bergonié, Incyte Biosciences International Sarl
retroperitoneal sarcomas sarcomes rétropéritonéaux, retroperitoneal sarcomas sarcomes rétropéritonéaux, Diseases [C] - Cancer [C04]
 
 
LYTPET, NCT00324467: Tailoring Treatment for B Cell Non-hodgkin's Lymphoma Based on PET Scan Results Mid Treatment

Active, not recruiting
2
150
Canada
Cyclophosphamide, Cytoxan®, Neosar®, Doxorubicin, Adriamycin ®, Rubex®, Vincristine, Oncovin ®, Vincasar Pfs ®, Vincristine Sulfate, LCR, VCR, Prednisone, Sterapred®, Sterapred® DS, Prednisone Intensol, Ondansetron, Zofran®, Zofran® ODT, Zuplenz®, Dexamethasone, Decadron®, Dexamethasone Intensol®, Dexpak® Taperpak®, Diphenhydramine, Aler-Dryl®, Benadryl®, Nytol®, Diphenhist®, Acetaminophen, Tylenol®, Ifosfamide, Ifex®, Isophosphamide, Mesna (IV), Mesnex®, Sodium 2-mercaptoethanesulfonate, Mesna (oral), Carboplatin, CBDCA, Etoposide, Etopophos®, VP-16, Rituximab, Rituxan®, PET Scan, Positron emission tomography (PET) scan
British Columbia Cancer Agency, Hoffmann-La Roche
Lymphoma, Non-Hodgkin, Advanced Stage Diffuse Large B-Cell Non-Hodgkin's Lymphoma
12/21
12/21
NCT02638428: Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Recruiting
2
90
RoW
CancerSCAN™, Ifosfamide, Carboplatin, Etoposide, Fludarabine, Cytarabine, Pazopanib, Sorafenib, Axitinib, Crizotinib, Dasatinib, Erlotinib, Everolimus, Imatinib, Ruxolitinib, Vandetanib, Vemurafenib, Trastuzumab
Samsung Medical Center, Ministry of Health, Republic of Korea
Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor, Relapsed Pediatric AML, Refractory Pediatric AML
12/21
12/23
NCT04224337: Phase II Study of Durvalumab ,Doxorubicin, and Ifosfamide in Pulmonary Sarcomatoid Carcinoma

Active, not recruiting
2
34
RoW
Durvalumab + doxorubicin + ifosfamide
Seoul National University Hospital
Carcinoma, Non-Small-Cell Lung
08/23
05/25
NCT01979393 / 2013-000762-11: IRCI Gynae Sarcomas, High Grade Uterine Sarcoma

Active, not recruiting
2
58
Europe
Cabozantinib, Placebo
European Organisation for Research and Treatment of Cancer - EORTC, Gynecologic Oncology Group, NHS Greater Glasgow and Clyde
Uterine Sarcoma
03/22
05/24
SAIS, NCT04356872: The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

Recruiting
2
45
RoW
Sintilimab, Doxorubicin Hydrochloride, ADM, Ifosfamide, IFO
Fudan University, Zhejiang Cancer Hospital, Tongji Hospital, Xijing Hospital, Shanghai Zhongshan Hospital
Sarcoma, Soft Tissue
03/22
03/23
2021-006229-23: Pilot phase II study of Selinexor in combination with Ifosfamide, Etoposide and Dexamethasone (SIDE) in patients with relapsed or refractory Peripheral T-cell Lymphomas. Studio pilota di fase II di Selinexor in combinazione con Ifosfamide, Etoposide e Desametasone (SIDE) in pazienti con linfoma a cellule T periferiche recidivato o refrattario.

Not yet recruiting
2
30
Europe
HOLOXAN, Selinexor, Decadron, Etoposide, [HOLOXAN], [Selinexor], [Decadron], [Etoposide], Powder for solution for injection/infusion, Tablet, Solution for injection, Concentrate for solution for injection/infusion, HOLOXAN - 1 G POLVERE PER SOLUZIONE INIETTABILE 1 FLACONCINO, DECADRON - 8 MG/2 ML SOLUZIONE INIETTABILE 3 FIALE DA 2 ML, ETOPOSIDE TEVA - 1 FLACONE 5 ML 20MG/ML
FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI"
peripheral T Cell lymphoma Linfoma a cellule T periferiche recidivato o refrattario, peripheral T Cell lymphoma Linfoma a cellule T periferiche recidivato o refrattario, Diseases [C] - Cancer [C04]
 
 
NCT04154189 / 2019-003696-19: A Study to Compare the Efficacy and Safety of Ifosfamide and Etoposide With or Without Lenvatinib in Children, Adolescents and Young Adults With Relapsed and Refractory Osteosarcoma

Completed
2
81
Europe, Canada, US, RoW
Lenvatinib, E7080, Ifosfamide, Etoposide
Eisai Inc., Merck Sharp & Dohme LLC
Osteosarcoma
06/22
08/23
NCT02445404: Compare Efficacy of CHOP Versus Fractionated ICED in Transplant-eligible Patients With Previously Untreated PTCL

Recruiting
2
134
RoW
CHOP, cyclophosphamide, cyclophosphamide, vincristine,prednisone, fractionated ICED, ifosfamide, carboplatin, etoposide, dexamethasone
Samsung Medical Center
Peripheral T-cell Lymphoma
06/22
06/23
NCT05050630: Phase II Trial of Tirelizumab Combined With R2-ICE Regimen in the Treatment of rrDLBCL/HGBL

Recruiting
2
73
RoW
TR2-ICE
Affiliated Hospital to Academy of Military Medical Sciences, Beijing Cancer Hospital, Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Age Range ≥16 Years, Gender Unlimited, Histopathology Confirmed Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma, Received Prior First-line Chemotherapy for DLBCL or HGBL, Failed to Reach CR for Four Cycles, or Relapsed, At Least One Positive Lesion According to the 2014 Lugano Criteria for Hodgkin's and Non-Hodgkin's Lymphoma, ECOG Physical Status Score is 0-3, The Researchers Judged That Life Expectancy Was at Least Three Months, Understand and Voluntarily Sign Written Informed Consent
07/22
07/23
ChiCTR1900025067: A prospective, open, single-center, non-randomized controlled trial for Anlotinib hydrochloride versus AI chemotherapy in the treatment of soft tissue sarcoma

Not yet recruiting
2
61
 
doxorubicin+ifosfamide ;Anlotinib hydrochloride, p.o.
Guangxi Medical University Cancer Hospital; Guangxi Medical University Cancer Hospital, CHIA TAI TIANQING (CTTQ) Pharmaceutical Co., Ltd.
Soft Tissue Sarcoma
 
 
AIEO, NCT04824352: Apatinib Plus IE Chemotherapy (Ifosfamide and Etoposide) for Relapsed or Refractory Osteosarcoma

Suspended
2
44
RoW
apatinib, IE chemotherapy
Peking University People's Hospital, Peking University Shougang Hospital
Effect of Drug, Toxicity, Drug
04/26
04/26
2023-000169-14: Clinical Study of High-Dose Treosulfan/Melphalan as Consolidation Treatment in Newly Diagnosed High-Risk and Very High-Risk Ewing Sarcoma Studio clinico su Treosulfan/Melfalan ad alte dosi come trattamento di consolidamento nel sarcoma di Ewing ad alto e altissimo rischio di nuova diagnosi

Not yet recruiting
2
60
Europe
Trecondi, Vincristina, Cyclophosphamide, Doxorubicin, Ifosfamide, Etoposide, Melphalan, Powder for solution for infusion, Solution for injection, Powder for injection, Concentrate for solution for infusion, Powder and solvent for solution for injection/infusion, TRECONDI 1 g, TRECONDI 5 g
Fondazione Santobono Pausilipon ONLUS, Medac Gesellschaft für klinische Spezialpräparate m.b.H.,
Ewing Sarcoma Sarcoma di Ewing, Ewing sarcoma, a bone tumor affecting children, adolescents and young adults Sarcoma di Ewing, un tumore osseo che colpisce bambini, adolescenti e giovani adulti, Diseases [C] - Cancer [C04]
 
 
NCT04012827: Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

Recruiting
2
108
RoW
Apatinib Mesylate, doxorubicin, ifosfamide, Apatinib
Sun Yat-sen University, Jiangsu HengRui Medicine Co., Ltd.
Soft Tissue Sarcoma
06/23
12/23
OAIE, NCT05277480: Apatinib With Ifosfamide Plus Etoposide for Relapsed or Refractory Osteosarcoma

Completed
2
81
RoW
Apatinib+IE, IE
Peking University People's Hospital, Jiangsu HengRui Medicine Co., Ltd.
Effect of Drug, Drug, Toxicity
06/23
11/23
MEGACEP, NCT02817958: Evaluation of Lymphadenectomy and Chemotherapy TIP on Inguinal Lymph Nodes in Squamous Cell Carcinoma of the Penis

Recruiting
2
37
Europe
Chemotherapy TIP, Chemotherapy TIP (paclitaxel, ifosfamide et cisplatine)
UNICANCER, National Cancer Institute, France
Penile Cancer, Squamous Carcinoma
09/26
09/28
NCT03736616: Acalabrutinib Plus RICE for Relapsed/Refractory DLBCL

Recruiting
2
47
US
Carboplatin, Ifosfamide, Etoposide, VP-16, Rituximab, Rituxan, Carmustine, BCNU, Cytarabine, ARA-C, Melphalan, Autologous HSCT, Autologous Hematopoeitic Stem Cell Transplantation, Acalabrutinib
Swedish Medical Center, Acerta Pharma BV
Diffuse Large B Cell Lymphoma
09/23
09/23
NCT04581265: Nab-PTX, Ifosfamide and Cisplatin in the Treatment of Pediatric Extracranial Germ Cell Tumor.

Not yet recruiting
2
43
NA
albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin
Sun Yat-sen University
Extracranial Germ Cell Tumor, Pediatric
11/23
05/24
ISG/OS-2, NCT01459484 / 2011-001659-36: ABCB1/P-glycoprotein Expression as Biologic Stratification Factor for Patients With Non Metastatic Osteosarcoma

Completed
2
225
Europe
Mifamurtide arm, Methotrexate, Cisplatinum, doxorubicin, ifosfamide, mifamurtide, 3 drugs arm, methotrexate, cisplatin, doxorubicine
Italian Sarcoma Group
Osteosarcoma
04/24
04/24
NCT04589754: Adriamycin and Ifosfamide Combined With Sintilimab

Recruiting
2
176
RoW
Sintilimab plus chemotherapy, Adriamycin-based chemotherapy
Sun Yat-sen University
Soft Tissue Sarcoma
12/25
07/26
NCT04665765: Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
2
41
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Polatuzumab Vedotin, ADC DCDS4501A, Antibody-Drug Conjugate DCDS4501A, DCDS4501A, FCU 2711, polatuzumab vedotin-piiq, Polivy, RG7596, Ro 5541077-000, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Rituxan, Rituximab ABBS, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, rituximab biosimilar TQB2303, rituximab-abbs, RTXM83, Truxima
City of Hope Medical Center, National Cancer Institute (NCI)
Diffuse Large B-Cell Lymphoma Unclassifiable, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Cell Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma
03/24
03/24
NCT02106988: Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma

Recruiting
2
40
US
Radiation Therapy, XRT, Dexamethasone, Decadron, Etoposide phosphate, VePesid, Ifosfamide, Ifex, Mesna, Mesnex, Carboplatin, Paraplatin
M.D. Anderson Cancer Center
Lymphoma
01/34
01/34
NCT06277154: MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma

Not yet recruiting
2
148
RoW
MASCT-I, Doxorubicin, Doxorubicin hydrochloride for Injection, Ifosfamide, Ifosfamide for Injection
HRYZ Biotech Co.
Leiomyosarcoma, Liposarcoma, Synovial Sarcoma, Angiosarcoma, Undifferentiated Pleomorphic Sarcoma, Epithelioid Sarcoma, Malignant Peripheral Nerve Sheath Tumors, Fibrosarcoma, Pleomorphic Rhabdomyosarcoma, Endometrial Stromal Sarcoma, Desmoplastic Small Round Cell Tumor
02/26
02/27
NCT00936936: High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors

Completed
2
64
US
Gemcitabine, Gemcitabine Hydrochloride, Gemzar, Docetaxel, Taxotere, Melphalan, Alkeran, Carboplatin, Paraplatin, Mesna, Mesnex, Ifosfamide, Ifex, Etoposide, VePesid, Stem Cell Transplant, SCT, Hematopoietic progenitor-cell infusion, PBPC
M.D. Anderson Cancer Center
Testicular Cancer
01/24
01/24
NCT03418038: Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia

Recruiting
2
80
US
Ascorbic Acid, 2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one, Asorbicap, C Vitamin, C-Long, Ce-Vi-Sol, Cecon, Cenolate, Cetane, Cevalin, L-Ascorbic Acid, VIT C, Vitamin C, Vitamin-C, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, JM8, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cytarabine, .beta.-Cytosine arabinoside, 1-.beta.-D-Arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-.beta.-D-Arabinofuranosylcytosine, 1-Beta-D-arabinofuranosyl-4-amino-2(1H)pyrimidinone, 1-Beta-D-arabinofuranosylcytosine, 1.beta.-D-Arabinofuranosylcytosine, 2(1H)-Pyrimidinone, 4-Amino-1-beta-D-arabinofuranosyl-, 2(1H)-Pyrimidinone, 4-amino-1.beta.-D-arabinofuranosyl-, Alexan, Ara-C, ARA-cell, Arabine, Arabinofuranosylcytosine, Arabinosylcytosine, Aracytidine, Aracytin, Aracytine, Beta-Cytosine Arabinoside, CHX-3311, Cytarabinum, Cytarbel, Cytosar, Cytosine Arabinoside, Cytosine-.beta.-arabinoside, Cytosine-beta-arabinoside, Erpalfa, Starasid, Tarabine PFS, U 19920, U-19920, Udicil, WR-28453, Dexamethasone, Aacidexam, Adexone, Aknichthol Dexa, Alba-Dex, Alin, Alin Depot, Alin Oftalmico, Amplidermis, Anemul mono, Auricularum, Auxiloson, Baycadron, Baycuten, Baycuten N, Cortidexason, Cortisumman, Decacort, Decadrol, Decadron, Decadron DP, Decalix, Decameth, Decasone R.p., Dectancyl, Dekacort, Deltafluorene, Deronil, Desamethasone, Desameton, Dexa-Mamallet, Dexa-Rhinosan, Dexa-Scheroson, Dexa-sine, Dexacortal, Dexacortin, Dexafarma, Dexafluorene, Dexalocal, Dexamecortin, Dexameth, Dexamethasone Intensol, Dexamethasonum, Dexamonozon, Dexapos, Dexinoral, Dexone, Dinormon, Dxevo, Fluorodelta, Fortecortin, Gammacorten, Hemady, Hexadecadrol, Hexadrol, Lokalison-F, Loverine, Methylfluorprednisolone, Millicorten, Mymethasone, Orgadrone, Spersadex, TaperDex, Visumetazone, ZoDex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16-213, VP16, VP-16, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Oxaliplatin, 1-OHP, Ai Heng, Aiheng, Dacotin, Dacplat, Diaminocyclohexane Oxalatoplatinum, Eloxatin, Eloxatine, JM-83, Oxalatoplatin, Oxalatoplatinum, RP 54780, RP-54780, SR-96669, Placebo Administration, Questionnaire Administration, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, Rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima, Ikgdar, Mabtas, Decitabine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Core Biopsy, BIOPSY, CORE, CORE CNB, Core Needle, Core Needle Biopsy, Needle Biopsy, Bone Marrow Aspiration, Bone Marrow Biopsy, Biopsy of Bone Marrow, Biopsy, Bone Marrow, Echocardiography, EC, ECHO, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), positron emission tomography scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, nuclear magnetic resonance imaging, Structural MRI, sMRI, Central Venous Cannula Insertion, Central venous catheter, Central Venous Catheter Placement, Portacath Placement, Port-a-cath Placement, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT SCAN, tomography
Mayo Clinic, National Cancer Institute (NCI)
Clonal Cytopenia of Undetermined Significance, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Lymphoma, Chronic Myelomonocytic Leukemia
12/25
03/26
NCT04860674: A Prospective Study of PD-1 Inhibitor Combined With ICE in the Treatment of Relapsed/Refractory Gray Area Lymphoma

Not yet recruiting
2
20
NA
PD-1 inhibitor +ICE, Icyclophosphamide, carboplatin, etoposide
Zhejiang Cancer Hospital
Gray Zone Lymphoma, Relapse/Recurrence, Chemotherapy Effect
04/24
04/24
ChiCTR2000038919: A multicenter phase II clinical study of albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin in the treatment of pediatric advanced, recurrent or refractory extracranial germ cell tumor.

Recruiting
2
43
 
albumin-bound paclitaxel (nab-PTX), ifosfamide and cisplatin
Sun Yat-Sen University Cancer center; Sun Yat-Sen University CancerCenter, Sun Yat-sen University Cancer center
Extracranial germ cell tumor
 
 
NCT01873326: Paclitaxel, Ifosfamide and Cisplatin (TIP) Versus Bleomycin, Etoposide and Cisplatin (BEP) for Patients With Previously Untreated Intermediate- and Poor-risk Germ Cell Tumors

Active, not recruiting
2
92
US
Paclitaxel, Ifosfamide, Cisplatin, Mesna, Bleomycin, Etoposide
Memorial Sloan Kettering Cancer Center, University of Southern California, Mayo Clinic, University of Pittsburgh, University of North Carolina, University of Chicago, Stanford University, University of Texas Southwestern Medical Center
Germ Cell Tumors
06/24
06/24
NCT06415318: TIP Regimen Combined With Triplizumab Neoadjuvant Therapy for Locally Advanced Penile Cancer

Not yet recruiting
2
25
NA
Paclitaxel + Ifosfamide + Cisplatin & Toripalimab
Sun Yat-sen University
Penile Cancer
06/27
12/27
NCT06393361: Chidamide+Decitabine Plus Anti-PD-1 Antibody in PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma.

Recruiting
2
60
RoW
Chidamide; Decitabine; Anti-PD-1 Antibody, Gemcitabine, Vinorelbine, Pegylated liposomal doxorubicin, Ifosfamide, Carboplatin, Etoposide, Brentuximab Vedotin, anti-PD-1 antibody.
Chinese PLA General Hospital
PD-1 Inhibitor Failed Patients With Classical Hodgkin Lymphoma
06/26
06/27
NCT00878254: Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Checkmark P2 data: ASH 2012
Nov 2012 - Nov 2012: P2 data: ASH 2012
Active, not recruiting
2
25
US
G-CSF, Filgrastim, Neupogen, Rituximab, Rituxan, Cyclophosphamide, Cytoxan, Cytarabine, AraC, Doxorubicin, Adriamycin, Etoposide, VP16, Ifosfamide, Ifex, Leucovorin, Folinic acid, Mesna, Mesnex, Methotrexate, MTX, Vincristine, Oncovin
University of Miami
Mantle-Cell Lymphoma
09/24
09/27
NCT04776525: Sequential Neoadjuvant Chemotherapy in Soft Tissue Sarcoma

Recruiting
2
49
Europe
Ifosfamide, Holoxan, Doxorubicin, Adriamycin
Oslo University Hospital, Haukeland University Hospital
Soft Tissue Sarcoma
09/26
09/36
NCT00077285: Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Active, not recruiting
2
65
US
filgrastim, carboplatin, cyclophosphamide, dexrazoxane hydrochloride, doxorubicin hydrochloride, etoposide, ifosfamide, irinotecan hydrochloride, vincristine sulfate, conventional surgery, radiation therapy
Memorial Sloan Kettering Cancer Center, National Cancer Institute (NCI)
Sarcoma
10/24
10/24
P+R-ICE, NCT05221645: Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma

Recruiting
2
65
Europe
Pembrolizumab, KEYTRUDA, Rituximab, MabThera, Ifosfamide, Carboplatin, Etoposide
University of Southampton, Merck Sharp & Dohme LLC
Diffuse Large B Cell Lymphoma
10/24
12/25
O-ICE, NCT02393157: Obinutuzumab and ICE Chemotherapy in Refractory/Recurrent CD20+ Mature NHL

Recruiting
2
25
US
Obinutuzumab, Gazyva, Liposomal ARA-C, Depocyte, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16
New York Medical College, Roswell Park Cancer Institute
Non-Hodgkin Lymphoma, Burkitt Lymphoma, Diffuse Large B-Cell Lymphoma, Primary Mediastinal B-cell Lymphoma, CD20+ Lymphoblastic Lymphoma, Follicular Lymphoma, Grade III
12/24
12/24
ChiCTR2200064503: Rituximab in combination with mesimide, ifosfamide, mitoxantrone liposome, and etoposide in the treatment of relapsed and refractory diffuse Large B-cell lymphoma: a prospective, single-arm, multi-center, Phase II clinical trial

Not yet recruiting
2
30
 
Mitoxantrone liposome injection + Ifosfamide + Rituximab + etoposide + mesna
37 Guoxue Alley, Wuhou District, Chengdu, Sichuan, China; West China Hospital, Sichuan University, CSPC Baike (Shandong) Biopharmaceutical Co. , Ltd.
lymphoma
 
 
NCT05821088: Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Recruiting
2
37
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized Tomography, CT, CT Scan, tomography, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Tafasitamab, Immunoglobulin, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain, Dimer, Monjuvi, MOR-00208, MOR00208, MOR208, Tafasitamab-cxix, XmAb5574
David Bond, MD
Recurrent B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Grade 3b Follicular Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Recurrent Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma
12/24
12/25
NCT03016871: Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Active, not recruiting
2
78
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo
City of Hope Medical Center, National Cancer Institute (NCI)
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
01/25
01/26
ChiCTR2200061723: A single-arm, prospective, multicenter clinical study of a modified MINE regimen based on liposomal mitoxantrone hydrochloride for the treatment of relapsed/refractory primary central nervous system lymphoma

Not yet recruiting
2
10
 
Mitoxantrone liposome+Ifosfamide+Mesna+Etoposide+CD20 antibody
The Second Hospital of Nanjing; The Second Hospital of Nanjing, China Shijiazhuang Pharmaceutical Group Ouyi Pharmaceutical Company limited
central nervous system lymphoma
 
 
TORNADO, NCT04968106: Neoadjuvant Chemotherapy and Retifanlimab in Patients With Selected Sarcomas

Recruiting
2
66
Europe
Doxorubicin, Ifosfamide, INCMGA00012, Retifanlimab
Institut Bergonié, Incyte Biosciences International Sàrl
Resectable Sarcoma
03/25
10/27
NCT05455918: Paclitaxel/Ifosfamide/Cisplatin Chemotherapy for High Risk Pediatric Germ Cell Tumor

Recruiting
2
42
RoW
TIP treatment (paclitaxel/ifosfamide/cisplatin)
Yonsei University
Pediatric Germ Cell Tumor
06/25
06/28
ChiCTR2000034375: TIP (paclitaxel + ifosfamide + cisplatin) Combined with Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer

Not yet recruiting
2
29
 
TIP (paclitaxel + ifosfamide + cisplatin)+Nimotuzumab+Triprilimab
Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Self-financing
Penile Caner
 
 
NCT06033820: Zanubrutinib+Lenalidomide+R-ICE in Relapsed/Refractory DLBCL

Recruiting
2
20
RoW
ZR2-ICE
RenJi Hospital
Diffuse Large B-cell Lymphoma Recurrent, Diffuse Large B Cell Lymphoma Refractory
06/25
06/25
RMS13, NCT01871766: Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy

Active, not recruiting
2
98
US
Vincristine, Oncovin®, Dactinomycin, Actinomycin-D, Cosmegen®, Cyclophosphamide, Cytoxan(R), Surgical Resection, Surgery, Radiation, Proton Beam Radiation, External Beam Radiation, Brachytherapy, Bevacizumab, rhuMab, VEGF, Avastin®, Sorafenib, Nexavar®, Myeloid Growth Factor, G-CSF, Filgrastim, Pegfilgrastim, Lymph Node Sampling, Irinotecan, Camptosar ®, Ifosfamide, Ifex ®, Etoposide, VP-16, Vepesid®, Etoposide Phosphate, Etopophos®, Doxorubicin, Adriamycin®, Dexrazoxane, Zinecard, ^1^1C-methionine, Contrast Media
St. Jude Children's Research Hospital
Rhabdomyosarcoma
07/25
06/30
NCT03383406: A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma

Enrolling by invitation
2
30
NA
Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy, IVAM
Asan Medical Center
Diffuse Large B Cell Lymphoma
12/25
12/25
NCT05124951: The Efficacy of WVI in Patients With Localized Basal Ganglia Intracranial Germ Cell Tumors

Recruiting
2
150
RoW
Whole-ventricle irradiation, Carboplatin/etoposide, Ifosfamide/cisplatin/etoposide, Second-look surgery
Beijing Tiantan Hospital
Intracranial Germ Cell CNS Tumor, Childhood
10/26
10/26
NCT01864109: Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

Active, not recruiting
2
83
US
Cyclophosphamide, Doxorubicin, Vincristine, Ifosfamide, Etoposide, Surgery, Radiation Therapy*, Temozolomide, Irinotecan, Mesna, Dexrazoxane, G-CSF
Memorial Sloan Kettering Cancer Center
Newly Diagnosed Ewing Sarcoma
 
 
NCT04322318: A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

Recruiting
2
221
Canada, US, RoW
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Doxorubicin, Adriablastin, Hydroxydaunomycin, Hydroxyl Daunorubicin, Hydroxyldaunorubicin, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Irinotecan, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Surgical Procedure, Operation, Surgery, Surgery Type, Surgery, NOS, Surgical, Surgical Intervention, Surgical Interventions, Surgical Procedures, Type of Surgery, Topotecan, Hycamptamine, Topotecan Lactone, Transabdominal Ultrasound, abdominal ultrasound, TUS, Vincristine, LCR, Leurocristine, VCR, Vincrystine, X-Ray Imaging, Conventional X-Ray, Diagnostic Radiology, Medical Imaging, X-Ray, Plain film radiographs, Radiographic Imaging, Radiographic imaging procedure (procedure), Radiography, RG, Static X-Ray, X-Ray
Children's Oncology Group, National Cancer Institute (NCI)
Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor, Stage III Kidney Wilms Tumor, Stage IV Kidney Wilms Tumor
07/27
07/27
NCT04684368: A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT

Recruiting
2
160
Canada, US, RoW
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Mesna, 2-Mercaptoethanesulfonate, Sodium Salt, Ausobronc, D-7093, Filesna, Mercaptoethane Sulfonate, Mercaptoethanesulfonate, Mesnex, Mesnil, Mesnum, Mexan, Mistabron, Mistabronco, Mitexan, Mucofluid, Mucolene, UCB 3983, Uromitexan, Ziken, Pegfilgrastim, Dulastin, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Neupopeg, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, Pegfilgrastim-apgf, Pegfilgrastim-bmez, Pegfilgrastim-cbqv, Pegfilgrastim-jmdb, Pegylated G-CSF, Pegylated GCSF, Pegylated Granulocyte Colony Stimulating Factor, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Tripegfilgrastim, Udenyca, Ziextenzo, Peripheral Blood Stem Cell Transplantation, PBPC transplantation, PBSCT, Peripheral Blood, Peripheral Blood Progenitor Cell Transplantation, PERIPHERAL BLOOD STEM CELL TRANSPLANT, Peripheral Stem Cell Support, Peripheral Stem Cell Transplant, Peripheral Stem Cell Transplantation, Questionnaire Administration, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Second-Look Surgery, Reoperation, Repeat Surgery, Second Look, Surgical Revision, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312
Children's Oncology Group, National Cancer Institute (NCI)
Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma, Immature Teratoma, Malignant Teratoma, Mixed Germ Cell Tumor, Pineal Region Germ Cell Tumor, Pineal Region Immature Teratoma, Pineal Region Yolk Sac Tumor, Suprasellar Germ Cell Tumor
12/29
12/29
NCT00788125: Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors

Terminated
1/2
7
US
carboplatin, dasatinib, etoposide phosphate, ifosfamide, microarray analysis, western blotting, immunohistochemistry staining method, laboratory biomarker analysis, therapeutic conventional surgery, radiation therapy
City of Hope Medical Center, National Cancer Institute (NCI)
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Sarcoma, Testicular Germ Cell Tumor, Unspecified Childhood Solid Tumor, Protocol Specific
04/10
07/22
NCT02227199: Brentuximab Vedotin, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma

Active, not recruiting
1/2
45
US
Brentuximab Vedotin, ADC SGN-35, Adcetris, Anti-CD30 Antibody-Drug Conjugate SGN-35, Anti-CD30 Monoclonal Antibody-MMAE SGN-35, Anti-CD30 Monoclonal Antibody-Monomethylauristatin E SGN-35, cAC10-vcMMAE, SGN-35, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16-213, VP-16, VP-16-213, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis
University of Washington, National Cancer Institute (NCI), Seagen Inc.
Recurrent Hodgkin Lymphoma, Refractory Hodgkin Lymphoma
03/20
09/25
ZUMA-1, NCT02348216 / 2015-005007-86: Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

Checkmark Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Dec 2022 - Dec 2022: Data from ZUMA-1 trial for R/R LBCL at ASH 2022
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Feb 2021 - Feb 2021: Presentation from ZUMA-1 trial for DLBCL at ASTCT 2021
Checkmark Presentation from ZUMA-1 trial for DLBCL at ASH 2020
More
Completed
1/2
307
Europe, Canada, US, RoW
Axicabtagene Ciloleucel, Yescarta®, Fludarabine, Cyclophosphamide, Levetiracetam, Tocilizumab, Dexamethasone, High-dose methylprednisolone, Bendamustine, Rituximab, Doxorubicin, Prednisone, Vincristine, Ifosfamide, Carboplatin, Etoposide, Gemcitabine, Oxaliplatin, Cisplatin, Methylprednisolone
Kite, A Gilead Company
Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
07/23
07/23
NCT02628405: R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
1/2
63
US
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Ifosfamide, Asta Z 4942, Asta Z-4942, Cyfos, Holoxan, Holoxane, Ifex, IFO, IFO-Cell, Ifolem, Ifomida, Ifomide, Ifosfamidum, Ifoxan, IFX, Iphosphamid, Iphosphamide, Iso-Endoxan, Isoendoxan, Isophosphamide, Mitoxana, MJF 9325, MJF-9325, Naxamide, Seromida, Tronoxal, Z 4942, Z-4942, Laboratory Biomarker Analysis, Lenalidomide, CC-5013, CC5013, CDC 501, Revlimid, Rituximab, ABP 798, BI 695500, C2B8 Monoclonal Antibody, Chimeric Anti-CD20 Antibody, CT-P10, IDEC-102, IDEC-C2B8, IDEC-C2B8 Monoclonal Antibody, MabThera, Monoclonal Antibody IDEC-C2B8, PF-05280586, Riabni, Rituxan, Rituximab ABBS, Rituximab ARRX, Rituximab Biosimilar ABP 798, Rituximab Biosimilar BI 695500, Rituximab Biosimilar CT-P10, Rituximab Biosimilar GB241, Rituximab Biosimilar IBI301, Rituximab Biosimilar JHL1101, Rituximab Biosimilar PF-05280586, Rituximab Biosimilar RTXM83, Rituximab Biosimilar SAIT101, Rituximab Biosimilar SIBP-02, rituximab biosimilar TQB2303, Rituximab PVVR, rituximab-abbs, Rituximab-arrx, Rituximab-pvvr, RTXM83, Ruxience, Truxima
Academic and Community Cancer Research United, National Cancer Institute (NCI)
Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Non-Hodgkin Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma
09/21
12/25
NCT03064867: Venetoclax Plus R-ICE Chemotherapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Active, not recruiting
1/2
65
US
Venetoclax, Rituximab, Rituxan, Ifosfamide, Ifex, Carboplatin, Paraplatin, Etoposide, VP-16, VePesid
Molly Gallogly
Diffuse Large B-cell-lymphoma
08/22
08/23
NCT03628131: Combination Chemotherapy With Pazopanib in Children and Adolescents With Relapsed/Refractory Solid Tumors

Not yet recruiting
1/2
46
RoW
Pazopanib, Ifosfamide, Carboplatin, Etoposide
Samsung Medical Center, Ministry of Health, Republic of Korea
Relapsed Pediatric Solid Tumor, Refractory Pediatric Solid Tumor
07/23
07/25
NICE-40, NCT04981899: A Study of Safety and Efficacy of PET-adapted Treatment With Nivolumab at the Fixed Dose 40 mg, Ifosfamide, Carboplatin, Etoposide () in Patients With Relapsed/Refractory Hodgkin Lymphoma

Recruiting
1/2
30
RoW
Nivolumab, Ifosfamide, Carboplatin, Etoposide
St. Petersburg State Pavlov Medical University
Hodgkin Lymphoma
10/23
10/24
TOUCH, NCT04425070: A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma

Hourglass Dec 2022 - Dec 2022 : First-patient-in of ARM-C of TOUCH trial in combination with tislelizumab for r/r/ peripheral T- and NK/T-cell lymphoma
Checkmark Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Nov 2022 - Nov 2022: Data from TOUCH trial for r/r peripheral T- and NK/T-cell lymphoma
Checkmark Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Dec 2021 - Dec 2021: Presentation of data from TOUCH trial for the treatment of NK - Cell lymphoma at ASH 2021
Active, not recruiting
1/2
56
RoW
ICE [ifosfamide+carboplatin+etoposide], GEMOX [gemcitabine+oxaliplatin], Tislelizumab
Antengene Corporation
Peripheral T-cell Lymphoma, NK/T-cell Lymphoma
12/24
12/24
NCT06239272: NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)

Recruiting
1/2
139
US
Surgical resection, Proton beam radiation therapy, Pazopanib, VOTRIENT®, Ifosfamide, Ifex, Doxorubicin, Adriamycin®, Rubex®, Selinexor, XPOVIO®
St. Jude Children's Research Hospital
Non-rhabdomyosarcoma, Adipocytic Neoplasm, Liposarcoma
06/34
06/37
ImmunoSarc, NCT03277924 / 2016-004040-10: Trial of Sunitinib and/or Nivolumab Plus Chemotherapy in Advanced Soft Tissue and Bone Sarcomas

Recruiting
1/2
270
Europe
Sunitinib 37.5 MG, Sunitinib 25 MG [Sutent], Sutent, Nivolumab 100 MG/10 ML [Opdivo], Opdivo, Epirubicin, Ifosfamide, Doxorubicin, Dacarbazine, Cisplatin, Methotrexate
Grupo Espanol de Investigacion en Sarcomas
Soft Tissue Sarcoma, Bone Sarcoma
06/25
06/25
NCT05813327: Neoadjuvant ADI-PEG 20 + Ifosfamide + Radiotherapy in Soft Tissue Sarcoma

Recruiting
1/2
35
US
ADI PEG20, PEGylated arginine deiminase, Ifosfamide, ifex, Radiotherapy, Mesna, sodium 2-mercaptoethane sulfonate
Washington University School of Medicine, Polaris Group
Soft Tissue Sarcoma, Sts, Sarcoma,Soft Tissue
01/26
01/28
NCT05590572: A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma

Not yet recruiting
1/2
148
RoW
Sulfatinib, Etoposide, Isophosphamide
Second Affiliated Hospital, School of Medicine, Zhejiang University, Chonnam National University, Peking University People's Hospital, Qilu Hospital of Shandong University, Ruijin Hospital, Shanghai Jiao Tong University Affiliated Sixth People's Hospital
Osteosarcoma
12/26
12/27
iMATRIX GLO, NCT05533775 / 2021-006326-48: A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma

Recruiting
1/2
65
Europe, US, RoW
Obinutuzumab, Glofitamab, Rituximab, Ifosfamide, Carboplatin, Etoposide, Tocilizumab
Hoffmann-La Roche
Mature B-Cell Non-Hodgkin Lymphoma
10/27
10/27
EPCORE NHL-2, NCT04663347 / 2020-000845-15: Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell Non-Hodgkin Lymphoma (B-NHL)

Checkmark Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 6 of EPCORE NHL-2 trial for r/r/ follicular lymphoma at ASH 2022
Checkmark Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Dec 2022 - Dec 2022: Data from arm 2b of EPCORE NHL-2 trial for r/r follicular lymphoma at ASH 2022
Checkmark Data from arm-4 of EPCORE NHL-2 trial for r/r DLBCL at ASH 2022
More
Recruiting
1/2
662
Europe, US, RoW
rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, R-CHOP, rituximab and lenalidomide, R2, rituximab and bendamustine, BR, rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin, R-DHAX/C, gemcitabine and oxaliplatin, GemOx, Epcoritamab, GEN3013, DuoBody®-CD3xCD20, EPKINLY™, rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone, R mini-CHOP, Lenalidomide, rituximab, ifosfamide, carboplatin, and etoposide phosphate, R-ICE
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
03/29
03/29
FaR-RMS, NCT04625907 / 2018-000515-24: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

Recruiting
1/2
1672
Europe, RoW
Irinotecan, Actinomycin D, Dactinomycin, Doxorubicin, Ifosfamide, Vincristine, Vinorelbine, Cyclophosphamide, Temozolomide, radiotherapy, Regorafenib
University of Birmingham
Rhabdomyosarcoma
06/30
06/30

Download Options